#1 Clinical Trials Search in Europe

Foscarnet Sodium Hexahydrate

This article discusses the use of Foscarnet Sodium Hexahydrate in clinical trials for treating acyclovir-resistant herpes simplex virus (HSV) infections in immunocompromised patients. Foscarnet is being studied as an alternative treatment option when standard antiviral medications like acyclovir are no longer effective. The trials aim to assess the safety and efficacy of Foscarnet in comparison to other treatment options for this challenging patient population.

Table of Contents

What is Foscarnet?

Foscarnet Sodium Hexahydrate, also known by its brand name Foscavir, is a medication used to treat certain viral infections[1]. It is particularly important for patients whose immune systems are weakened (immunocompromised) and who have developed resistance to other antiviral medications, such as acyclovir[1].

Medical Conditions Treated

Foscarnet is primarily used to treat acyclovir-resistant mucocutaneous Herpes Simplex Virus (HSV) infections in immunocompromised patients[1]. Mucocutaneous refers to areas involving both mucous membranes and skin, such as the mouth, genital area, or anal region. This medication is particularly valuable when other treatments have failed.

Immunocompromised patients who might benefit from foscarnet include:

  • People with HIV/AIDS
  • Organ transplant recipients
  • Patients undergoing chemotherapy
  • Those on long-term immunosuppressive treatments

How Foscarnet Works

Foscarnet works differently from other antiviral medications like acyclovir. It directly inhibits viral DNA replication by blocking the virus’s DNA polymerase enzyme[1]. This mechanism of action makes it effective against viruses that have become resistant to other antiviral drugs.

Administration and Dosage

Foscarnet is administered as an intravenous solution, meaning it’s given directly into a vein[1]. The typical concentration is 24 mg/ml. The dosage is usually calculated based on the patient’s weight, with a maximum daily dose of 120 mg/kg (milligrams per kilogram of body weight)[1].

Treatment duration can last up to 42 days, depending on the patient’s response and the severity of the infection[1]. The total amount of foscarnet given over the entire treatment period should not exceed 5040 mg/kg[1].

Clinical Trials and Research

Foscarnet is being studied in clinical trials, particularly in comparison to newer antiviral medications. One such trial, named PRIOH-1, is investigating the efficacy and safety of a new drug called pritelivir compared to “Investigator’s Choice” treatment (which includes foscarnet) for acyclovir-resistant HSV infections in immunocompromised patients[1].

In this trial, foscarnet serves as a comparator drug, which means it’s being used as a standard treatment to evaluate the effectiveness of the new medication[1]. This highlights the current importance of foscarnet in treating resistant HSV infections.

Potential Side Effects and Precautions

While foscarnet can be an effective treatment, it may cause side effects. Some potential adverse effects mentioned in the clinical trial data include[1]:

  • Impairment of renal function
  • Seizures
  • Genital irritation and/or ulcerations
  • Extremity paresthesia (tingling or numbness)
  • Nausea
  • Changes in blood cell counts (granulocytopenia, anemia, leukopenia, thrombopenia)
  • Electrolyte imbalances (hypokalemia, hypocalcemia, hypomagnesemia)
  • Diabetes insipidus
  • Injection site reactions
  • Psychiatric disorders, including anxiety and aggression

Due to these potential side effects, foscarnet is typically used when other treatments have failed or are not suitable. Patients receiving foscarnet should be closely monitored by their healthcare providers[1].

Aspect Details
Drug Name Foscarnet Sodium Hexahydrate (Foscavir)
Formulation 24 mg/ml Solution for Infusion
Administration Route Intravenous Use
Maximum Daily Dose 120 mg/kg
Maximum Total Dose 5040 mg/kg
Treatment Duration Up to 42 days
Target Population Immunocompromised patients aged ≥16 years (≥18 in some countries) with acyclovir-resistant mucocutaneous HSV infections
Primary Endpoint Cure rate (all lesions healed) within 28 days of treatment
Key Secondary Endpoints Time to lesion healing, recurrence rates, pain reduction, viral shedding cessation

FAQ

  • What is Foscarnet Sodium Hexahydrate? Foscarnet Sodium Hexahydrate is an antiviral medication used to treat certain viral infections, particularly in cases where other antiviral drugs like acyclovir are not effective. It is administered as an intravenous solution.
  • Who are the target patients for these clinical trials? The trials focus on immunocompromised patients aged 16 years and older (18 years in some countries) who have acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infections. These patients may have conditions such as HIV, organ transplants, or be on long-term immunosuppressive treatments.
  • What is the main goal of the clinical trials involving Foscarnet? The main goal is to investigate the efficacy and safety of Foscarnet in treating acyclovir-resistant HSV infections in immunocompromised patients. The trials compare Foscarnet to other treatment options and assess its effectiveness in healing lesions and reducing viral shedding.
  • How is Foscarnet administered in these trials? Foscarnet is administered as an intravenous solution. The maximum daily dose is 120 mg/kg, and the maximum total dose amount is 5040 mg/kg over a treatment period of up to 42 days.
  • What are some of the key outcomes measured in these trials? The trials measure several outcomes, including the cure rate (complete healing of lesions), time to lesion healing, recurrence rates, pain reduction, cessation of viral shedding, and development of resistance to the trial medication.

Ongoing Clinical Trials on Foscarnet Sodium Hexahydrate

  • Study on Pritelivir for Treating Acyclovir-Resistant Herpes Simplex Virus in Immunocompromised Patients

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Belgium France Germany Greece Italy

Glossary

  • Acyclovir-resistant (ACV-R): A condition where the herpes simplex virus (HSV) no longer responds to treatment with acyclovir, a common antiviral medication.
  • Mucocutaneous HSV infection: An infection caused by the herpes simplex virus that affects both mucous membranes (such as the mouth or genital area) and the skin.
  • Immunocompromised: Having a weakened immune system, which can be due to conditions like HIV, organ transplantation, or long-term use of immunosuppressive medications.
  • Foscarnet: An antiviral medication used to treat certain viral infections, particularly when other antivirals like acyclovir are not effective.
  • Clinical failure: When a treatment does not improve the condition after a specified period, in this case, no improvement after at least 7 days of treatment with standard antiviral medications.
  • Genotypic/phenotypic resistance testing: Laboratory tests that determine if a virus has genetic mutations or characteristics that make it resistant to certain medications.
  • Lesion healing: The process of complete healing of skin or mucous membrane sores caused by viral infections.
  • Viral shedding: The release of virus particles from an infected person, which can potentially spread the infection to others.
  • Polymerase chain reaction (PCR): A laboratory technique used to detect and measure the amount of viral genetic material in a sample.
  • Recurrence rate: The frequency at which an infection or symptoms return after initial treatment or healing.

References

  1. http://clinicaltrials.eu/trial/study-on-pritelivir-for-treating-acyclovir-resistant-herpes-simplex-virus-in-immunocompromised-patients/